Research programme: HSPPC-70-I - Antigenics

Drug Profile

Research programme: HSPPC-70-I - Antigenics

Alternative Names: HSPPC-70-I

Latest Information Update: 30 Aug 2006

Price : $50

At a glance

  • Originator Antigenics
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bacterial infections; Tuberculosis

Most Recent Events

  • 30 Aug 2006 Discontinued - Preclinical for Bacterial infections in USA (unspecified route)
  • 30 Aug 2006 Discontinued - Preclinical for Tuberculosis in USA (unspecified route)
  • 19 Oct 2005 Preclinical trials as a delivery aid in Tuberculosis vaccine in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top